Precision medicine is often defined as the right treatment at the right dose at the right time for the right patient. Someday, clinicians may be able to target more precise and individualized therapies based on each patient's genetic variants, biochemistry, behavior and lifestyle, and environment. But to reach that lofty goal, the still-infant field of precision medicine will need to encourage new animal-modeling approaches, particularly for diagnosing and treating rare disorders, according to a 2018 report by the National Academy of Sciences entitled
Advancing Disease Modeling in AnimalBased Research in Support of Precision Medicine: Proceedings of a Workshop.
"We need to push the envelope with animal models and get more creative, " says Kent Lloyd, a workshop coorganizer and director of the Mouse Biology Program at the University of California, Davis.
The first stage of precision medicine has been driven by rapid advances in gene sequencing and data analytics. Sequencing an individual's genome today costs about $1000, down from $95 million in 2001, and the price is expected to drop even further. To identify potential new precision therapies, scientists are mining genomic and patient data with increasingly powerful artificial intelligence (AI) tools.
A growing number of animal model studies will be needed to validate whether a particular gene variant or combination of variants causes a disorder in humans. "There will be more opportunities to do larger numbers of these basic animal and in vitro research studies coming out of these shared large databases, " says Daryl Pritchard, a workshop presenter and senior vice president of science policy at the Personalized Medicine Coalition, an advocacy and education organization.
Although data-driven approaches should continue, they often take too long to find effective treatments, particularly for rare diseases, says Lloyd. Even large databases may not include enough people with very rare diseases to study.
Animal models and human clinical studies are typically done by research teams that may not formally interact. "We need to move animal models into closer physical proximity to the patients and allow that to drive discovery, " says Lloyd. "Mouse hospital" coclinical trials have studied both human patients and research animals. Some mouse hospitals insert tumors from individual patients into immunocompromised mice. Researchers can use these mouse models to test each tumor's sensitivity to treatments, which can inform the next stage of patient care. "This allows you to grow that tumor in a mouse and then treat those mice with different drug regimens and pick a therapy that would best fit that particular patient, " Lloyd says. "Findings from animal models can be fed back into improving diagnostics and therapies for patients. "
Researchers have also created genetically engineered animal models based on each tumor's genetics, allowing the models to function as surrogates for a human patient, according to John Clohessy, director of the Preclinical Murine Pharmacogenetics Facility at Beth Israel Deaconess Medical Center and Harvard Medical School. The goal is to create the first state-of-theart research program with personnel who are trained in diseased mouse care, husbandry, and therapeutic treatments, in vivo imaging, behavioral testing, and surgical procedures. Each patient's disease has a unique molecular characterization, progression, and response to treatments that can be tested in animal models. Clohessy envisions advanced mouse-hospital research programs in tandem with human clinical trials being developed throughout the country and the world, with facilities credentialed and accredited. The data would be shared and centrally deposited.
Scientists could use a mouse hospital system to study biological markers not only in the genome but also in the proteome-how cells express genes-and other omics. Researchers will eventually need to integrate environmental and behavioral factors in animal models to learn about potential interactions with genetic variants.
But developing new genome-based and mouse-hospital approaches could provoke political opposition from animal rights organizations and others, says Elizabeth Heitman, a science and medicine ethicist at the University of Texas Southwestern Medical Center. The percentage of Americans who believe it is "morally acceptable" to perform medical testing on animals has dropped from 65 percent in 2001 to 51 percent in 2017. "How do you engage people around complex science, particularly around something as complex as genetic research? No one knows the answer. But growing numbers of research efforts funded by the National Science Foundation and the National Institutes of Health are focused on trying to answer that question. "
